Newsroom

Neurodegenerative Disease RUO Assays

Featured News

Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research

Beckman Coulter Diagnostics, a global leader in advanced diagnostics, today announced availability of new Research Use Only (RUO) blood-based biomarker immunoassays designed to advance neurodegenerative disease research. These assays are intended to assess p-Tau217, GFAP, NfL, and APOE ε4 biomarkers, which are emerging as the most important biomarkers in neurodegenerative diseases research, including interventional clinical trials.

Read more
bone marrow aspirate

Featured News

Beckman Coulter and Scopio Labs Add World’s First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership

 

Beckman Coulter, a clinical diagnostics leader, and Scopio Labs, a medtech company that develops digital cell morphology workflow solutions, today jointly announced expansion of its long-term partnership to include a global distribution agreement of Scopio’s Full-Field Bone Marrow Aspirate™ (FF-BMA) Application. Scopio’s X100 / X100HT with FF-BMA Application are CE-Marked.

Read more

News Releases

Learn more about the latest news and happenings at Beckman Coulter. 

See all news releases  

  • July 30, 2024

    Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

    Read more
  • July 24, 2024

    Beckman Coulter’s DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.’s Annual Supplier Innovation Celebration

    Read more
  • May 29, 2024

    Beckman Coulter Secures FDA Clearance for Heart Failure Assay on DxI 9000 Immunoassay Analyzer

    Read more
  • May 7, 2024

    Beckman Coulter and MeMed Extend Partnership Advancing Host Immune Response Diagnostics

    Read more
Global Public Relations
Name Jeff Tarmy
Address Beckman Coulter World Headquarters
Brea California
Phone +1-617-467-7537

Stay Connected